Eflornithine oral - Cancer Prevention Pharmaceuticals

Drug Profile

Eflornithine oral - Cancer Prevention Pharmaceuticals

Alternative Names: CPP-1X; DFMO; Difluoromethylornithine

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Prevention Pharmaceuticals
  • Developer Cancer Prevention Pharmaceuticals; Vanderbilt University Medical Center
  • Class Basic amino acids; Diamino amino acids; Small molecules
  • Mechanism of Action Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis; Neuroblastoma; Gastric cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastric cancer; Neuroblastoma
  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 14 Sep 2017 Chemical structure information added
  • 17 Jul 2017 Phase-II clinical trials in Gastric cancer (Prevention) in USA (PO, Tablet)
  • 17 Jul 2017 Phase-II clinical trials in Gastric cancer in USA (PO, Powder)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top